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  The present study has been designed to investigate the effect of different ligands 
on the dermal absorption of copper.  
   Eight copper chelating agents, ethylenediaminetetraacetate (EDTA), glycine and 
alanine, diethylenetriaminepentaacetic acid (DTPA), homopiperazine, N,N’-di 
(aminoethylene)-2,6-pyridine-dicarbonylamine (PrDH), N-[2-(2-aminoethylamino) ethyl] 
picolinamide (H(555)-N) and N,N’-bis[aminoethyl] propanediamide (6UH) were selected 
and permeability coefficient Kp of copper complexes at room temperature through a 
Cerasome 9005 measured using a modified Franz cell.  The order of permeability 
coefficient was found to be Gly > H(555-N) > EDTA > 6UH > Homop. > Alan. > PrDH 
> DTPA > *CuCl2.2H2O (Copper(II) Chloride Dihydrate)   
 The permeability coefficient (Kp) values of complexes with amino-acids were 
comparable to those found in the literature.  All the ligands were found to enhance the 
diffusion of copper when compared to CuCl2, with enhancement factors ranging from 1.6 
to 6.1.    
 In order to explain the diffusion enhancement, octanol/water partition coefficients 
(log Ko/w) of seven complexes at pH 7.00 were measured.  The order of lipohilicity of the 
copper complex was found to be Gly > CuH(555-N) > 6UH > EDTA > PrDH > Homop > 
DTPA.  However, the complexes were still lipophilic with log Ko/w  = -3. 
Linear regression of the measured log Kp, with both MW and log Ko/w failed.  
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AAS    Atomic Absorption Spectroscopy  
CAT    Enzymes catalase 
CuEDTA     Copper(II)-Ethylenediaminetetraacetate 
CuDTPA    Copper(II)-Diethylenetriaminepentaacetic acid 
CuGlyc  Copper(II)-Glycine 
CuAlan  Copper(II)-Alanine 
CuBIDPAP  Copper(II)-1,15-bis(N,N-dimethyl)-5,11-dioxo-8-(N-benzyl)-
1,4,8,12,15-pentaazapentadecane  
CuPrDH  Copper(II)-N,N’-di (aminoethylene)-2,6-pyridine-dicarbonylamine 
CuAcet.  Copper(II)-Acetylsalicylate 
CuHomop.  Copper(II)-Homopiperazine or 2H-1,4-Diazepane 
CuPrDPr Copper(II)-N,N’-bis[2-(2-pyridyl)-methyl]pyridine-2,6-
dicarboxamide 





   diamine 
Cu[H(555)-N] Copper(II)-N-[2-(2-aminoethylamino) ethyl] picolinamide 
Cu[H2(555)-N] Copper(II)-N,N’-[2,2’-azanediylbis (ethane-2,1-dyil)]  
   dipicolinamide 
Cu(6UH)    Copper(II)-N,N’-bis [aminoethyl] propanediamide 
CuDMDM   Copper(II)-N,N’ bis [2-(dimethylamino) ethyl] propanediamide 
DMARDs    Disease Modifying Antirheumatic Drugs 
ESTA   Equilibrium Simulation for Titration Analysis 
GSSH   Glutathione-peroxidase 





HCL   Hollow-cathode lamp 
H-1    Hydroxide ion (OH
-
) 
ML    Metal-ligand 
ML2    1 Metal coordinated to 2 ligands 
MQ-water   Milli-Q water 
NSAIDs    Non-Steroidal Anti-Inflammatory Drugs  
PAMPA   Parallel Artificial Membrane Permeability Assay 
PBS    Phosphate buffered saline 
PDMS   Poly (demethylsiloxane) 
PMT   Photomultiplier tube 
QSARs   Quantitative structure-activity relationships 
RA    Rheumatoid Arthritis  
SAAS   Slow-acting anti-arthritic drugs 
SOD    Superoxide dismutase 









J Flux in g/cm
2
s 
Kp Permeability coefficient in cm/s 
Ko/w Octanol/water partition coefficient 
∆P Hydrostatic pressure in Pa 
∆h Height fluid in m 
φ       Fluid density in Kg/m
3
 
g       Acceleration due to gravity in m/s
2
 
βpqr Formation constant of complex 
Io Incident light 
It Transmitted light 
SE  Standard Error 
SD Standard Deviation  
R
2
 Coefficient of correlation 
MW Molecular weight in g/mol 
D
0
   The diffusivity of hypothetical molecule having zero molecular weight 
h     The membrane thickness 
f    Constant which accounts for the difference between the partitioning domain presented 
by octanol and that presented by the membrane lipids 
 β’ Constant which includes a conversion factor for the substitution of molecular weight 
for molecular volume.  
Km Membrane/donor vehicle partition coefficient of the drug  
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1.1 Inflammatory Disease 
  An inflammation is a protective response elicited by injury (or destruction of 
tissues) and is characterised by increasing blood supply, activation of defence 
mechanisms, pain (dolor), heat (calor), redness (rubor), swelling (tumour) and loss of 
function (arthritis).  The beginning of the tissue repair process is required to re-establish 
normal function but if the inflammation persists, the result will be a lack of normal 
function which is recognised as “chronic inflammation” (e.g. Rheumatoid Arthritis).   
The inflammatory response can be provoked by physical, chemical and biological 
agents, including exposure to excessive amounts of sunlight, x-rays and radioactive 
materials, corrosive chemicals, extremes of heat and cold and infectious agents such as 
bacteria, viruses and other pathogenic microorganisms.
1 
1.2  Rheumatoid Arthritis  
The first written reference to arthritis sounds very similar to what is known now as 
rheumatoid arthritis.  In 123 AD, a text from India called Caraka Samhita describes a 
disease where swollen, painful joints initially strike the hands and feet, then spread to the 
body, causing loss of appetite, and occasionally fever.  Year 1939 brought the first 
autoimmune theory into the picture.  Sr. McFarlane Burnet (head of Research Institute of 
Melbourne, Australia) proposed that autoimmunity, the process by which the body's 
defence system malfunctions and attacks its own tissues, causes many arthritis conditions.   
This theory holds true today.
2
 
Rheumatoid arthritis (RA) is therefore defined as a chronic inflammation, 
systemic autoimmune disorder that causes the immune system to attack the joints, tissues 
around joints and other organs in the body as well, where it causes inflammation 
(arthritis) and destruction.  The concept “arthritis” means joint disorder featuring by 
inflammation (a basic way in which the body reacts to infection, irritation or other injury) 
and Rheumatoid (from Rheumatic: pains caused by rheumatism which is any of several 
pathological conditions of the muscles, tendons, joints, bones, or nerves, characterized by 
discomfort and disability).  It’s a progressive inflammatory disease that has the potential 
to cause joint destruction, functional disability and can lead to substantial loss of 
mobility.  It has long been suspected that an infection, various bacteria and/or viruses 






RA affects approximately 5% of the World’s population, with women being 
affected two to three times more often than men.  Its can occur at any age but is more 
common between 40-60 years old.  There’s no cure.
4
 
1.3 Immune System Response  
The immune system response is a normal and essential response of the body to a 
harmful stimulus (antigen, bacteria…) characterized by painful inflammation of synovial 
joints which along with angiogenesis leads to the formation of a tissue called the 
“pannus”.4-7 The development of pannus causes erosion of cartilage and bone as shown in 
Figure 1.1. 
                           
Figure 1.1 Normal and Arthritis joint
8
 
The development of bone and cartilage erosion will be followed by swelling, 
stiffness and loss of joint function (destruction of connective tissue).  Progressive 
degeneration of the joint appears as a result of unrestrained inflammation until the joint 
becomes deformed
9
 as shown in Figure 1.2.
10
 




 Figure 1.2.2  
Later stage 





1.4 Treatment of Symptoms associated with RA  
 The medical approach to the treatment of any disease requires the removal of the 
causal agent(s), interruption of pathological mechanism and alleviation of symptoms or 
remission of disease.  Since the cause of RA still unknown, the primary requirement is 
not included in therapeutic strategy but the second and third requirements are included by 
alleviation of symptoms through anti-inflammatory agents.4  
 The following are some of the most important agents currently used by most 
rheumatologists according to a recent review by Sanz and Alboukrek.11 
1. Non-Steroidal anti-inflammatory drugs (NSAIDs) 
2. Disease modifying anti-rheumatic drugs (DMARDs) 
3. Glucocorticoids. 
1.4.1 NSAIDs 
NSAIDs are the most commonly used because they are well tolerated by patients 
and decrease the inflammation resulting from disease or injury.  They include salicylates 
such as aspirin (acetylsalicylic acid), the first commercially available NSAID introduced 
into medicine by Frederick Bayer and Company in 1889.
12
 It is the most useful drug for 
treating RA.  If taken in high dosage it can suppress the inflammation
1
 but has a complex 
dosing schedule and dangerous side effects (e.g. gastropathy, renal toxicity and renal 
insufficiency) if overdoses are taken.
12-13
 There are also a series of non-salicylates which 
are generally weak carboxylic or enolic acid derivatives.
9
 Ibuprofen and acetaminophen 
are widely used for their ability to decrease inflammation and pain.  NSAIDs have also 
analgesic and antipyretic properties but cannot prevent progression of joint destruction or 
organ damage.1 
In 1971, J. R. Vane proposed the hypothesis that the anti-inflammatory effects of 
NSAIDs were due to their ability to inhibit cyclooxygenese (COX) enzymes pathway of 
prostaglandin (PG) synthesis.
1
 A mechanism was proposed by McCarthy D.J (1989) and 
validated by Weismann M.H (1995) enouncing that: a variety of free radicals derived 
from molecular oxygen, including superoxide, hydroxyl and perhydroxyl radicals are 
involved in biosynthesis of prostaglandins and provoke cell injury.  The NSAIDs may act 
as free radical foragers (antioxidants) by preventing the activity of various facilitators of 





Examples of NSAIDs are shown in Table 1.1 below. 
Table 1.1 Non steroidal anti-inflammatory drugs 
1
 



















Salsate Azapropazone Piroxicam Isoxicam 
 
Phenylbutazone Tolmetin Orgotein Etodolac 
 
Indomethacin Fenbufen   
 
Mefenamic acid Tiaprofenic 
 
  




Suprofen Flufenamic acid   
 
 Tenoxicam   
 
 Ibuprofen   
 
 Naproxen   
 
 Ketoprofen   
 







Diseases modifying anti-rheumatic drugs (DMARDs) are known to have some 
effect on changing progression of RA.  However, they are toxic and patients need to be 
re-evaluated by their physicians.  They are also slow-acting drugs and have been 
classified as slow-acting anti-arthritis drugs (SAARDs).  Therefore, they must be 
administered over a long period of time (4 – 6 months) before a therapeutic benefit can be 
achieved.
1,9,15-19
 Their dosage, assimilation, side effects and toxicity are given in Table 
1.2 
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There is also another series of drugs called “synthetic corticosteroids” which 
occur naturally in the body and take part in many physiological chemical reactions.  An 









The glucocorticosteroids are considered to be potent, fast-acting anti-
inflammatory agents such as cortisone, prednisone and dexamethasone.  They act to 
reduce heat, swelling and tenderness at the inflamed joint and have proved to be the best 
for combating inflammation.  However, their mode of anti-inflammatory action is 




The corticosteroids on the other side are not considered to have disease-remitting 
potential, although this has been reported recently to protect against joint erosion but the 




The glucocorticosteroids can be administered orally, intra-articularly or at peri-
articular sites of local inflammation and their side effects on patients can be dramatic 
depending on dose and duration of use.  Side effects on patients are gastritis, ulceration 
and severe myopathy.  Other complications including effect on bone, gastrointestinal 
tract, glucose intolerance, increased susceptibility to infections and impaired wound 





 It was said previously that the treatment of disease requires: removal of the causal 
agent(s), interruption of pathological mechanism and alleviation of symptoms or remission 
of disease. Unfortunately none of the current drugs (NSAIDs, DMARDs and 
glucocorticosteroids) have managed to treat the disease efficiently but they have tried to 
interrupt the pathology mechanism, alleviate symptoms and stop the side effects: 
 
 Gastropathy, Renal toxicity and Renal insufficiency (NSAIDs) 
 Skin rash, proteinuria and blood dyscrasia (DMARDs) 
 Dermatitis, nausea, anaemia, aplastic anaemia and leucopoenia (DMARDs) 
 Cramps, abdominal distension and diarrhea (DMARDs) 
 Suppression of the pituitary-adrenal axis, gastritis, ulceration and severe 
myopathy (glucocorticosteroids). 
 Gastrointestinal tract, glucose intolerance, increased susceptibility to 





This inefficiency of current drugs against arthritis has challenged scientists to 
develop an anti-inflammatory drug having very few side effects.  In 1960, Bonta showed 
that copper compounds possess anti-inflammatory activities in animals with lower 
toxicity and Sorenson confirmed this findings.
1,9,25-27
 Therefore, copper compounds have 
been proposed for further research as potential anti-arthritic agents.  
1.5 Motivation for study 
1.5.1 Copper and Rheumatoid Arthritis 
  Copper occurs as the metal in oxidation states (0), (I), (II) and unstable (III).  
Copper occurs as Cu(II) ion in aqueous solution.
9
 
    Copper is an essential trace element that acts as a cofactor for a variety of 
enzymes by virtue of its ability to accept and donate electrons under physiologic 
conditions.
2
 It is an essential component of the following enzymes;
4,9,28
 
1.  The free radical scavenger- superoxide dismutase (SOD) – required for the 
destruction of superoxide radicals. 
2. Cytochrome c oxidase – involved in oxidative metabolism, brain functioning, 
haem and phospholipids synthesis.  
3. Tyrosine – for the synthesis of dihydroxyphenyl-alanine which is subsequently 
transformed to melanin which is required for pigmentation. 
4. Lysyl oxidase - required for connective tissue in the lungs and bones. 
  Copper is one of the most abundant metallic elements in the human body 
following iron, calcium, potassium, magnesium and sodium. The body of a healthy male 
(70 kg) contains 110 mg of copper, much as skeleton (46 mg), skeletal muscle (26 mg), 
liver (10 mg), brain (8.8 mg) and blood (6 mg).  The normal human body contains 80-120 
mg of copper compared to Fe 4-5 mg and Zn 1.4-2.3 mg.  Metabolic balance studies 
show that people with daily intakes of 2-5 mg of copper absorb 0.6 - 1.6 mg (32%).
9
  







 The richest dietary sources of copper are animal liver, crustacean, shell fish, dried 
fruits, nuts and chocolate.  Dietary copper is generally absorbed in the stomach and small 
intestine, from where it is transported to the liver by the blood as a serum albumin 
complex.  It is in the liver that copper is processed and stored as a metallothionein 




  Table 1.3 shows normal human copper concentrations in various biological media 
and daily excretion levels.
30
 




Tissue Humans Daily excretion (μg) 
Whole body 800 - 1300 μg L
-1
  
Serum/plasma 800 - 1750 μg L
-1
  
Urine 12 - 80       μg L
-1
 30 – 70 
Bile 4.0             μg L
-1
 2500 
Duodenal fluid 0.17           μg L
-1
  400 – 2200 
Synovial fluid 0.2 – 0.5     μg L
-1
  
  Most of the ingested copper is excreted via the bile, the major excretory route, 
thus preventing tissue toxicity.  Trace amounts of copper are excreted via urine except in 
cases of copper overload.  Excess copper in the tissue leads to the production of 
damaging free radicals and subsequent DNA cleavage.
28
   
  In blood plasma, at least 90% of copper is irreversibly bound to ceruloplasmin in 
a non-exchangeable form, while about 10% is reversibly bound to serum albumin and 
less than 1% is distributed amongst low molecular weight (l.m.w) complexes, 




  Serum albumin (SA) has been considered to facilitate the transport of trace metals 
between tissues and blood and it is a major metal binding protein in the body, with about 
40 μg of copper able to bind to the albumin contained in 1ml of human plasma.  Albumin 






 The proposed structure of major Cu(II) binding site in HSA is shown in Figure 
1.3.  The metal ion is bound to the α-NH2 nitrogen, two peptide nitrogens and the 




                          
 
         Figure 1.3 Copper binding sites in Human Serum Albumin (HSA). 
 
  It has been observed that serum levels of copper are significantly increased during 
acute phases of RA inflammation, returning to normal with remission.   This rise in 
serum copper is due to an increase in ceruloplasmin concentration and represents a 
physiological response to inflammation.  It has however been shown that ceruloplasmin 
is a powerful antioxidant and could thus provide protection against cellular destruction, 
which may be the reason for its increased synthesis.  This would however bring about 
decrease in the concentration of serum albumin copper, as well as of the labile low 
molecular weight copper complexes.
9
 
 The mechanism of development of Rheumatoid Arthritis disease can be summarized 













Serum levels of 
copper in the 
blood 
Increase of concentration in 
ceruloplasmin: protein which 
binds copper irreversibly  
Decrease in the concentration 
of serum albumin copper and 





  Therefore, two ways have been proposed by which copper concentration can be 
adjusted; either from serum albumin by direct complexation using a powerful ligand or 
from ceruloplasmin using destructive chelators (e.g. penicillamine). 
1.5.2 The Anti-inflammatory role of copper 
  Historically copper has been used therapeutically for over 300 years, and the 
copper bracelet specifically has long been used as a folk remedy for the treatment of 
arthritis.  Cupriphores from sweat solubilises and promotes copper dermal absorption into 
the blood stream.
36-37
   
  Sorenson
25
 and Jackson et al.
32-33
 have shown that Cu(II) complexes are effective 
in reducing the inflammation associated with RA, enhancing bio-availability of copper 
and reducing their toxicity.
38-39
  
  The beneficial role of copper in minimizing inflammation has been attributed to 
its redox activity, particularly the ability of copper in such enzymes as SOD to remove the 
highly pro-inflammatory superoxide radical anion O2
-
.  The superoxide radical O2
-
 has 
been implicated in the promotion of arthritis due to its ability to degrade hyaluronic acid 
(HA) which is an important component of the synovial fluid maintaining internal joint 
connection by acting as lubricant.
9
 
  The dismutation of O2
-
 by copper in SOD is summarized as follows; 
Cu(II) + O2
-










               H2O2 + O2         (1.3) 
  Equations 1.1, 1.2 and 1.3 explain the antioxidant role of copper in SOD by 
reducing the radical O2
-
 to hydrogen peroxide (H2O2) which in cells will be converted to 









1.6 Aims and Objectives of the research  
 Cu(II) complexes can be administered orally or by intravenous injection.   Although 
these two methods are easy drug administration routes injection is painful and orally the 
complex would have to tolerate the harsh conditions in the stomach.  Therefore, dermal 
absorption is proposed as the best route of administration because it is slow (no acute 
response), tolerable and painless.  However, the efficacy of this route depends on the 
ability of the drug to pass through the skin.
9  
The aim of this study then was to investigate 
the effect of different ligands on the dermal absorption of copper.  This was done using 
the following steps: 
 Selecting model systems whereby the permeability of copper can be studied, either by 
an artificial or biological membrane. 
 Building and testing an appropriate apparatus to measure dermal flux (Franz Cell). 
 Selecting a membrane. 
 Measuring passive transport through the membrane as a function of time. 
 Calculating permeability coefficient. 
 Measuring octanol/water partition coefficient. 
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2.1  Dermal Absorption study 
2.1.1 Skin1-4  
 The skin is the outermost tissue and the largest organ of the body.  Its major 
function is to act as a barrier to the exterior environment (bacteria, harmful chemicals, 
ultraviolet light and temperature). It also prevents water loss and regulates body 
temperature. 
 The skin is essentially composed of three layers: epidermis, dermis and hypodermis 
(or Subcutis) as shown in Figure 2.1. 
 
                  Figure 2.1 Diagram of skin layers
5
 
 The epidermis contains 5 layers named respectively from top to bottom: stratum 
corneum, stratum licidum, stratum granulosum, stratum spinosum and stratum basale as 
shown in Figure 2.2   
 







  The stratum corneum (in Latin "stratum" = "layer" and "corneum" = "horny" so 
stratum corneum = horny layer) is essentially composed of 15 to 20 cells layers thick 
(keratin, protein), water and intercellular lipids as shown in Figure 2.3: 
       
     Figure 2.3 Diagram of Stratum corneum
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              The lipids consist of neutral lipids (60-80%) and sphingolipids (15-35%).  The 
neutral lipids are composed of free sterols, free fatty acids, triglycerides, n-alkanes of C19 to 
C34 and squalene. Sphingolipids are composed of 80% ceramides and 20% of 
glycosphingolipids.  The presence of an important mass of lipids gives the stratum corneum 
its lipophilic nature.  This top layer of the skin is extremely important for the skin barrier 
function.  
 In terms of the passage of chemicals through skin, the stratum corneum is 
essentially a lipidic layer, which interfaces with an aqueous medium beneath it.  The 
transport of lipophilic chemicals is through the stratum corneum, and as these compounds 
must transfer directly into an aqueous medium, a highly lipophilic compound will remain 
in the stratum corneum.
8 
 Thus, for the development of QSARs (Quantitative structure-activity relationships), 
descriptors of hydrophobicity are likely to be highly influential.  However, descriptors for 
molecular size and hydrogen bonding (which may describe non-covalent interactions with 







2.1.2 Selection of model system for permeability study  
  The in vitro study of copper(II) absorption through the skin is generally studied by 
measuring passive transport through, either a biological membrane or an artificial 
membrane.  An excellent membrane selected for permeability studies must allow the 
diffusion of the metal, be obtained and conserved easily, not limited to species (age, sex, 
weight, colour, size…) and give results close to the reality of diffusion through human 
skin 




Samples of biological membranes are generally obtained from human or animal 
skins and are characterised by age, sex, site targeted and origin.  They are stored in a 
freezer or frozen in liquid nitrogen. 
  The tape-stripping technique of human stratum corneum is widely used as 
method for studying the kinetics and penetration depth of drugs.  Its consists of stripping 
off most of the horny layer (corneocytes) of stratum corneum from adhesive tape.
14
  
Note that hairs and all fatty material must be removed before skin extraction and after 
being frozen, the skin membrane must be thawed at room temperature before the 
experiment. 
 2.1.2.2 Artificial membrane 
A variety of polymers have been selected as artificial membrane such as poly 
(dimethylsiloxane) PDMS, liposome (modelled stratum corneum) which is composed of 
horny layer lipids (liquid crystalline system), silastic (silicone), phospholipids and 









2.1.2.3 Difference between model membranes 
A biological membrane is dependent on the time they were obtained, the 
conditions of conservation and treatment.   The age, sex and weight have to be specified 
for a biological membrane.  These considerations are necessary for artificial membranes.  
2.1.2.4 Selection of model membrane 
Because of the reasons above, an artificial membrane was selected for the 
permeability study.  
The artificial membrane used in this study was “Cerasome 9005”.  This 
membrane is a lipid solution which mimics human stratum corneum.  Cerasome 9005 
was purchased from Germany (Lipoid GmbH, Frigenstr.4, D-67065 Ludwigshafen, 2008) 
and possess the following characteristics: Consistency (aqueous, transparent to opaque 
dispersion), colour (off-white), solid matter (10%), Phosphorus (0.11%), pH (7.1) and 
mean particle size (200 nm).  
2.1.3 Diffusion 
 A drug can across a membrane either by passive or active diffusion.  Passive 
diffusion occurs from a region of high concentration to a region of low concentration and 
does not require an external energy source while active diffusion occurs from a region of 
low concentration to a region of high concentration and requires energy and a 
biochemical carrier to ferry the drug across the membrane.  
For passive molecular diffusion, Fick’s law of diffusion states that; the amount of 
material (M) flowing through a unit cross-section (S) of a barrier in unit time (t), is 







                     (1) 
J= flux in g/cm
2
s; S= cross section of barrier in cm
2
; dM/dt = rate of diffusion in g/s; (M= 
mass in g; t = time in sec) 
  The flux is also proportional to the concentration gradient dC/dx, which is 




                
dX
dC
DJ                (2) 
D=diffusion coefficient of a drug in cm
2
/s; C=concentration of drug in g/cm
3
;  
X =distance in centimetres of movement perpendicular to the surface of the barrier. 
 The diffusion coefficient D is a physical property of the drug molecule which is  
dependent on temperature, pressure, solvent properties, and chemical nature of the 
diffusant (drug). 
 The theoretical relation existing between the flow of diffusion (J), the 
permeability coefficient (Kp) and the partition coefficient (Ko/w) can be demonstrated 
from Fick’s law giving the flow of diffusion of a solute through a membrane: 
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DJ m                (3) 
This equation can be integrated (considering the membrane as a thin and homogeneous 
layer): 





              (4) 
As the relation between the concentrations of solute in membrane (Cm) and in aqueous 
solution (Ci) is given by the equation: 









Assuming that the partition equilibrium of the complexes at each membrane interface is 
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Considering the initial concentration only, the relation between permeability coefficient 
(Kp, cm/s) and steady-state flux is given by the equation: 






                (9) 
Whereby C i
'
 is the initial permeate concentration in donor solution of drug and J is its 
mass passing through a unit area S of the membrane in unit time t. 
 
2.1.4 Partition Coefficient 
Partition coefficient is a measures hydrophobicity of a compound.  The measure 
of hydrophobicity can be expressed as the logarithm of partition coefficient between 1-
octanol and an aqueous phase.
21-22, 27
  For Cu(II)-complex, this may be given as; 
 
  
Log Poct/wat.= Log                          (10) 
            [Cu2+]wat 
Where  [Cu2+]org and [Cu
2+
]wat represent respectively the total concentrations of Cu(II) in 
1-octanol and aqueous phases. 
 




2.2 Method and Equipment  
       Amongst the most widely used methods for studying in vitro permeation are the 
Franz diffusion cell and PAMPA method. 
2.2.1 Franz Diffusion Cells 
The Franz diffusion cell is the common method used in permeation study.  It is 
based on vertical diffusion between donor and acceptor phase.  The following figure 





Figure 2.4 Normal Franz cell apparatus 
 
 A = donor compartment; B = acceptor compartment; C = membrane; D = O-ring;  
E = water jacket; F = stirring bar; G = sampling port. 
Note that the membrane is generally mounted between the cell compartments; an O-ring 
is used to position and seal the membrane and the clamp serves to hold together the two 
cell compartments.  The receiver phase is thermostated at 37°C by circulating water 
through an external water jacket and the diffusion is done vertically under the influence 
of gravity. 
A. Advantages 
 Industry standard, acceptor phase can be stirred and thermostated.    
Can use artificial or natural membranes and is reusable.  
B. Disadvantages 






2.2.2  Parallel Artificial Membrane Permeability Assay (PAMPA) 
 The Parallel Artificial Membrane Permeability Assay (PAMPA) is a rapid 
technique for studying many compounds at once.
24
 
The method consists of a 96-well filter plate placed in a receiver plate (used as 
permeation acceptor) and pre-coated with a lipid membrane (used as permeation donor).   
The two wells are coupled together, incubated for 5 hours at room temperature, 
separated afterwards and the concentrations of compounds from both compartments 




 Figure 2.5 Parallel Artificial Membrane Permeability Assay apparatus 
 
A. Advantages 
 Fast, 96 samples concentrated at a time, can use lipid as artificial membrane.  
 Small, can use small amounts of sample, cheap and dispensable equipment. 
B. Disadvantages  
 Cannot stir receiver phase and cannot thermostat only one phase.  
 Cannot use biomembranes. 
 
2.2.3  Choice of Method and Equipment  
   After analysing both methods the Franz diffusion cell was chosen because it is 
cheap and 17 compounds were planned to be analysed in this study.  Also the solution 
needed for AAS analysis meant that a larger receiver phase was needed.  However, the 




2.2.4 Modified Franz Diffusion Cell  
One of the problems with the Franz cell is that it is difficult to make, however it is 
commercially available.  Also because of the vertical arrangement, care has to be taken 
so as not to trap air between the two phases.  For this reason a modified Franz diffusion 
cell was designed and built.   
Again to simplify construction the water jacket around the receiving vessel was 
eliminated.  The horizontal design meant that assembly was easy and no air pockets 
formed.  It was also possible to stir both cells.  The whole system could be thermostated 
in a temperature controlled environment, but it was not possible to thermostat only the 
receiver phase. 
Figure 2.6 below shows details of the modified Franz diffusion cell made in our 
laboratory. 
                          
                 
      Figure 2.6 Modified Franz cell apparatus 
The modified Franz diffusion cell is based on Pascal's law or the Principle of 
transmission of fluid-pressure which states that "pressure exerted anywhere in a confined 
fluid is transmitted equally in all directions throughout the fluid.
26 
 
∆P = φ g (∆ h) 





ΔP is the hydrostatic pressure given in Pascal in the International System of Units (SI 
system), or the difference in pressure at two points within a fluid column, due to the 
weight of the fluid; 
φ 
is the fluid density (in kilograms per cubic meter in the SI system); 
g is acceleration due to gravity (normally using the sea level acceleration due to Earth's 
gravity in meters per second squared); 
Δh is the height of fluid above the point of measurement, or the difference in elevation 
between the two points within the fluid column (in meters in SI). 
In addition to Pascal’s law, 
  ∆P donor = ∆Preceptor, means ∆h donor = ∆h receptor                      (12) 
Note that the difference of height between acceptor and donor phase will affect the 
“Steady state of diffusion”.  Therefore, it’s recommended to keep the level on the two 
cylinders constant.   
2.3  Selection of Ligands for permeability study 
2.3.1 Introduction  
   A series of anti-inflammatory drugs found on the market, some common ligands 
and synthetic ligands have been studied which are listed as follows:  
-       Anti-inflammatory drugs: diclofenac sodium salt, propionic acid, acetylsalicylic 
acid and salicylic acid. 
-       Some common ligands: ethylenediaminetetraacetate (EDTA), glycine and alanine 
(Amino-acids), diethylenetriaminepentaacetic acid (DTPA) and homopiperazine. 
-       Synthetic ligands: N,N’-di(aminoethylene)-2,6-pyridine-dicarbonylamine (PrDH), 
1,15-bis(N,N-dimethyl)-5,11-dioxo-8-(N-benzyl)-1,4,8,12,15-pentaazapentadecane 





-(pyridin-2-ylmethyl) ethane-1,2-diamine [555-N], N-[2-(2-
aminoethylamino)ethyl]picolinamide [H(555)-N], N,N’-[2,2’-azanediylbis(ethane-
2,1-dyil)]dipicolinamide [H2(555)-N], N,N’-bis[amino ethyl] propanediamide 





2.3.2 Complexation of ligands with Copper at pH 7.00 
   The selection was based on complexation of ligands with Cu(II) at pH 7.00.  
Several ligands were rejected after screening because the copper  precipitated as Cu(OH)2 
after their pH was adjusted to 7.00.    These ligands were too weak to keep the copper in 
solution.  
   From all previous compounds cited above, only eight compounds did not form a 
precipitate, so they were selected.  The ligands which were selected and studied in dermal 
absorption are presented as follows: 
 
1. Ethylenediaminetetraacetate (EDTA) 
2. Glycine and alanine 
3. Diethylenetriaminepentaacetic acid (DTPA) 
4. Homopiperazine (Homop) 
5. N,N’-di(aminoethylene)-2,6-pyridine-dicarbonylamine (PrDH) 
6. N-[2-(2-aminoethylamino) ethyl] picolinamide [H(555)-N] 
7. N,N’-bis[aminoethyl] propanediamide (6UH). 
 
2.3.3 ESTA (Equilibrium Simulation for Titration Analysis) software  
   The program ESTA calculates the distribution of species present in an equilibrium 
system as a function of the pH of the solution.
27 
   ESTA software requires: 
- Stability Constant or formation constant βpqr: constant for the formation of a 
complex from reagents at specific temperature and ionic strength.  Refers to the 
equilibrium below, where p, q and r are the stoichiometric coefficients of the 
components in the complex 
  pM + qL + rH   MpLqHr          (13) 
βpqr =                          (14) 
- Ratio or concentrations of metal and ligand. 
- The temperature and ionic strength are generally fixed. 











     The distributions of copper complexes were determined in the pH range 2-11 by 
using the ESTA library of computer speciation programs at 298K and an ionic strength of 































































































































(b) % Distribution of H(555-N)-copper 




(a) % Distribution of Glycine-copper system 
(1:2 ratio) as function of pH 
(c) % Distribution of PrDH-copper system 
(1:1 ratio) as function of pH 
(d) % Distribution of EDTA-copper system 


































    
  
 
   
 
  Figures 2.7 shows that calculated speciation of Cu(II)-glycine (a), Cu(II)-H(555-
N) (b), Cu(II)-PrDH (c), Cu(II)-EDTA (d), Cu(II)-DTPA (e), Cu(II)-Homop (f), Cu(II)-
(6UH)  (g) and Cu(II)-Alan.(h) systems as a function of pH.  The normal convention of 
MpLqHr has been used to indicate the stoichiometry of the different species.  Water of 



































(e) % Distribution of DTPA-copper system 
(1:1 ratio) as function of pH 
(f) % Distribution of Homop.-copper system 
(1:2 ratio) as function of pH 
(g) % Distribution of 6UH.-copper system 
(1:2 ratio) as function of pH 
(h) % Distribution of Alan.-copper system 





2.4 Determination of Copper concentration 
2.4.1 Atomic Absorption Spectroscopy
28-29
 
2.4.1.1 Introduction  
Spectroscopy is considered to have started in 1666, with Newton’s discovery of 
the solar spectrum.  Wollaston repeated Newton’s experiment in 1802 and reported that 
the Sun’s spectrum was intersected by a number of dark lines.  Fraunhofer investigated 
these lines and in 1823 was able to measure their wavelengths.  Kirchhoff (1859) and 
Fraunhofer were observing Atomic Absorption and Emission. 
Atomic Absorption Spectroscopy (AAS) is the term used when the radiation 
absorbed by atoms is measured.  The application of AAS to analytical problems was 
delayed because of the apparent need for very high resolution to make quantitative 
measurements.  In 1953, Walsh overcame the obstacle by use of a line source which was 
pursued further and published by Alkemade in 1955.  
 
Atomic Absorption Spectroscopy is summarized diagrammatically in Figure 2.8. 
    
AAS            Absorption radiation    
   νjo=   
   Figure 2.8 Atomic Absorption radiation diagram   
Where; 
- The horizontal lines represent different energy levels in an atom 
-  Eo is the term used for lowest energy level (ground state) 
- Ej represents greater energy (higher) than Eo 
- A solid vertical line refers to a transition involving the absorption of energy as 
radiation. 
 The energy of the radiation absorbed or emitted is quantized according to 
Planck’s equation (equation 15),   
    E = hν           (15) 
 
Ej – Eo 






- h is Plank’s constant 
- ν is the frequency of the radiation  
- E is the energy difference between the two energy levels in the atom. 
 The frequency is related to wavelength by following formula, 
    λ = C/ν          (16) 
Where, λ is the wavelength and C as speed of light.  
2.4.1.2 Principles and Instruments 
AAS is a technique for determining the concentration of a particular metal 
element in a sample.  Based on Beer-Lambert law of absorption of UV or visible light by 
gaseous atoms which states that the absorbance “A” is equal to the logarithm of the 
intensity of the incident light (Io) over the intensity of the transmitted light(It) or is 
proportional to the thickness “l” through which the light is transmitted and to the 






o ..             (17) 
Where, A is the absorbance 
Io is the incident light and It the transmitted light 
k is the absorption coefficient or molar absorptive (quantity of light absorbs by 1cm of a 
1 molar solution). 
l is the thickness or path length measured generally in centimetre. 
c is the concentration of the substance or element (metal). 
Atomic Absorption Spectroscopy operates with following steps: 
- The liquid sample is evaporated and atomized by injection into a flame 
- Atomization of atoms in Flames: the emission spectrum of the element under study 
produced in the light source is passed through an “absorption cell”.  The important 
function of this absorption cell is to produce metal atoms in the ground state from the 




-  This is the most difficult and critical process within the whole AA procedure, the 
success or failure of an analysis is virtually dependent upon the effectiveness of the 
atomization. 
- The Hollow-cathode lamp (HCL) considered as source of light is used to determine 
the contained element, provide the analytical light line for the element of interest and a 
constant yet intense beam of the analytical line. 
- The nebulizer sprays the sample into the flame and sucks up liquid sample at a 
controlled rate, create a fine aerosol for introduction into the flame and mix of aerosol, 
fuel (acetylene) and oxidant (compress air) thoroughly for introduction into flame. 
- The Monochromator isolates analytical lines, photons passing through the flame and 
removes scattered light of other wavelength from the flame.  In doing this, only a 
narrow spectral line impinges on the PMT. 
- Photomultiplier tube (PMT) as a detector, PMT determines the intensity of the 
analytical line exiting the monochromator. 
- Detection Limit is defined generally as the smallest concentration (in µg/l) or amount 
(in g) of the element to be determined that can be detected with 95% probability. 
2.4.2 Linear Regression Analysis
30
 
The aim of Linear Regression Analysis is to compare a linear equation of 
absorbance in terms of concentration for a particular analyst with the known reference 
equation. 
2.4.2.1 Analysis aspects for linear calibration 
It aims to determine the calibration curve and check its statistical significance 
with such required to be significant (p ‹ 0.05) though highly significant (p ‹ 0.01) is 
preferred. 
2.4.2.2 Estimation of unknown concentration X 
By re-expressing the fitted linear equation or calibration line Y= a + bx, the 
unknown X value can be estimated as  




Where Y is the average of all absorbance (Y) in calibration and X is the unknown 
concentration.  
 An estimate of the error associated with the predicted X value is called Standard 
Error SE(X) and given by: 
SE(X)= Sy/x √1/m + 1/n + (Y –  Y)                          (19)                                                  




Sy/x is the regression standard deviation 
m is the number of replicate response measurements made on the unknown test   material 
or number of readings 
n is the number of data pairs in the calibration experiment 
Y is the mean of the experimental responses.  
Y is the average of all absorbance (Y) in calibration 
Sxx is the correct sum of squares for X from equation 18  
a is the intercept  
b is the least squares estimate of (slope parameter) and it’s given by equation 20 
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2.4.2.3 Uncertainty in Measurement: Standard Deviation
31
 
The broad aims of performing measurements in science are to increase our 
knowledge about some physical quantity, which is referred to as the measurand.  We 
indicate this incomplete state of knowledge of measurand by a quantity known as the 
uncertainty. A measurement result in science is meaningless without a quantitative 
statement of the uncertainty associated with it.  
One of the goals of measurement is to minimise the uncertainty associated with 
the measurand, this can be achieved by good experimental design as well as by collecting 
as much data as possible.  Many books use the term “error” but there’s a big difference 
between “error” and “uncertainty.” 
Error is an idealized concept that denotes the difference between the measured 
value and “a true value” of that quantity.  Since the “true value” is never known, neither 
is the error.  Uncertainty on the other hand is a well-defined term that can be calculated 
meaningfully.  
 The uncertainty associated with the spread in repeated measurements is referred 
to as the standard deviation of the mean, S, and is calculated using the equation 22 
below: 




d i                 (22) 
Where    Σ means “the sum of” 
   Xi = a particular value of the measurement 
               X = the mean value 
   di = Xi – X  
   N = the number of the measurements.  
 Therefore, the final answer will be given by equation 23 below: 
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3.1  Preparation of Copper Complexes 
10mM or 5mM of copper complexes were prepared from CuCl2.2H2O (purchased 
from Merck) and the different ligand in MilliQ-water (MQ-water).  The pH of the 
solutions was adjusting to 7.00 using concentrated NaOH or HCl.   
Different metal/ligand ratios were used depending on the ligand so as to avoid 
formation of a precipitate.  Table 3.1 lists the copper-ligand ratios used.  
Table 3.1 Ratio of different Copper Complexes 










 Ligands PrDH, H(555-N) and 6UH were synthesized in our laboratory.
1-3
 Glycine 
and EDTA were purchased from Merck. Alanine, DTPA and Homopiperazine were 
purchased from SIGMA-ALDRICH.   
  
3.2  Modified Franz Diffusion Cells 
A modified Franz cells was designed based on a normal Franz cell.
4
 Three 
modified Franz cells were made in which two had 50cm
3
 of volume cylinders and one 
had 25cm
3







Figure 3.1 shows the apparatus used to study diffusion of copper complexes. 
                               
                                      Figure 3.1 Modified Franz cells apparatus 
Where; 
1. Donor phase filled either with 25ml or 50ml of Copper complex 
2. Acceptor phase filled with blank solution (MQ-water) 
3. 0.0131g of artificial membrane. 
4. Passive diffusion direction 
5. Clamp 
6. Stirrer bar 
7. Magnetic Stirrer 
8. Burette Stand with clamp.  
The artificial membrane was made using filter paper (Macherey-Nagel) of 3.14 
cm
2
 discs and thickness 0.12cm.  The filter paper was submerged in a Cerasome 9005 
lipid solution purchased from Lipoid GmbH (Germany), dried for a few minutes at room 
temperature and then weighed.  The amount of lipid absorbed was determined by mass 
difference and was typically 0.0131g. 
The experiments were performed at room temperature with samples being 
collected at different times. 
Note that PBS was not used to stabilize the pH as is normally done in biological 
measurements.  This is because it coordinates to the copper(II) and hence disturbs the 
equilibrium being studied.  Speciation calculation using ESTA and experiments using 




1ml of aqueous phase  
        (Aq.Ph) 
3.3       Partition Coefficient 
The shake flask method was used to measure partition coefficients where the 
organic phase was 1-octanol pre-saturated with water.
5
 Figure 3.2 shows the different 
steps used to measure the partition coefficient of Cu(II). 
 
 
                                  Step1 
         40ml of 1-octanol  
 
                                                                                   Add 10ml of copper complex, 
        shake for 5min and stand   
      





                   Step3   A                                                                 B 
   
                                                                                                        
                                                                                                                         
         
Add 7ml of HNO3 5%         
shake and stand 
                   Step4 A                                                               B 
                                                                                                Aqueous phase ready 
                                                                                                        for copper measurement  
                                                                                                        by Atom. Absorption 
Step5                       Aq. Ph considered as  
                                       Org. Ph in copper measurement 
                          ready for Atom. absorption 





 Aq. Ph. 














Add  HNO3 5% 
38ml of organic 






Different steps present in Figure 3.2 are explained as follows:  40ml of 1-octanol, 
pre-saturated with water, were mixed with 10 ml of the aqueous complex solution and 
shaken for 5 min.  After shaking, the bottle was allowed to stand for 5 min so that the two 
layers could separate.  1 ml of the aqueous layer and 38 ml of the organic layer were 
removed using micropipettes. 
The aqueous layer was diluted to 10 ml using 5% v/v HNO3.  The organic layer could not 
be analysed directly using AAS and so the copper first had to be back extracted into an 
aqueous phase.  This was done using 7 ml of 5% v/v HNO3 solution.  The concentrations 
of copper in the two layers were then measured using AAS. 
 Because of the very different concentrations of copper found in the two layers (1-octanol 
and water) after AAS analysis of different samples, the experiments were performed 
using different volumes until reasonable concentrations were obtained for AAS analysis.  
These volume differences were of course taken into account when calculating the 
partition coefficients. 
Note that the AAS method used does not determine the concentration of the complexes 
species, but the total concentration of Cu(II) in each phase.  Therefore, the calculation of 
partition coefficient is based on total concentration rather than concentration of any 
individual species.  Where one species predominates under the conditions used, it is 













3.4 Atomic Absorption Spectroscopy 
3.4.1 Working Conditions  




   
 




Table 3.2 Working Conditions 
 
Copper Lamp 3mA  
Fuel Acetylene 1.5units/70pka 
Support  Compress air 350pka 
Wavelength  324.7nm  
Time 2sec  
Abs. exp. Factor 1  
Slit Width 1nm  
Spectral Band Pass(Abs.) 50  
Detection limit 0.03-10μg/ml  
  
 




3.4.2 Calibration of Atomic Absorption Spectrometer  
The calibration of the atomic absorption spectrometer was done using a Cu(II) 
standard (1000mg/l) purchased from SIGMA.  Concentrations of 1ppm, 2ppm, 5ppm, 
7ppm, 10ppm, 12ppm and 15ppm of copper standard solution were prepared.
6
 
Figure 3.4 shows a typical AAS calibration curve. 

































Figure 3.4 above shows a typical calibration curve. In the concentration range 
used, a linear curve was obtained with R
2
 = 0.99 ± 0.02.  Linear regression analysis was 
used to determine the unknown concentration and their standard deviations (Equations 14 
and 15, section 2.4.2.2). 
3.4.3 Validation of Modified Franz cells  
Literature results are not available for the diffusion of Cu(II) through the 
Cerasome membrane.  For this reason the reproducibility of the experimental set up was 
tested using [CuDTPA] at pH 5.33.  The experiment was repeated twice using a donor 
phase concentration of 635ppm giving a receptor phase concentration of 14.6 ± 1.1 ppm 
after 6hrs.  The standard deviation in the copper AAS analysis (3 replicates) was much 
lower (0.01), most of the overall error coming from the reproducibility of membrane 
preparation.  An overall error of ≈ 7% was deemed acceptable and is in line with 
literature measurements using a normal Franz cell.  Note that the diffusion at this low pH 
is much higher than that reported later at pH 7.0. 
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One of the objectives of this work was to establish if different ligands were able to 
promote the dermal absorption of Cu(II).  This was done by measuring the effect of the 
ligands on the rate of diffusion of Cu(II) through a Cerasome membrane as a model for 
skin and comparing these results with partition coefficient determined in 1-octanol.  The 
results are given below. 
4.0 Dermal absorption 
4.1 Diffusion in Franz cells 
4.1.1 Effect of time on diffusion 
The effect of time on the amount of copper diffusing through the membrane was 
studied using alanine and homopiperazine.  The effect of these two ligands on the 
diffusion of Cu(II) was studied for 36hrs.  The results are presented in Table 4.1 and 
Figure 4.1.  From this it can be seen that there is a slow induction period of ~8hrs during 
which time an equilibrium is set up between the donor phase and the membrane.  
Thereafter, there is a steady state flux of copper into the receiver phase.  This is shown by 
the straight line from 12hrs to 36hrs.  
Table 4.1 Diffusion of Cu(II) in the presence of Alanine and Homopiperazine 
through Cerasome 9005 membrane for 36hrs at pH 7.00 
 
                                 Cu(II) conc.(ppm)  
Time (h) Homopiperazine  Alanine 
2 0.03 ± 0.64 0.03 ± 0.65 
4 0.5 ± 0.6 1.0 ± 0.6 
6 2.1 ± 0.6 2.8 ± 0.6 
8 3.9 ± 0.5 5.8 ± 0.5 
12 11.0 ± 0.5 15.6 ± 0.5 
    24 35.4 ± 1.2 57.6 ± 0.1 






























Figure 4.1 Copper diffusion of CuHomop and CuAlan through Cerasome 9005 membrane at pH 7.00 
Having established that a steady-state flux was obtained between 8 and 36 hrs, the 
diffusion of other copper complexes was studied for 24hrs.  The results are shown in 
Table 4.1 and Figure 4.2.  Included in the Table 4.2 are results of CuCl2.2H2O without 
any ligand added. 
Table 4.2 Concentration (ppm) of Cu(II) in receiver phase in the presence of 































2 1.2 ± 0.6 0.2 ± 0.6 0.1 ± 0.6 1. 2 ± 0.6 0.03 ± 0.65 0.3 ± 0.6 0.2 ± 0.6 0.03 ± 0.01 
 
 
0.6 ± 0.6 
 
 
4 2.6 ± 0.5 0. 8 ± 0.6 1.0 ± 0.6 5.8 ± 0.5 0. 5 ± 0.6 1.2  ± 0.6 0.5 ± 0.6 1.04 ± 0.01 
 
 
1.2 ± 0.6 
 
 
6 4.9 ± 0.5 3.3 ± 0.5 2.8 ± 0.5 10.8 ± 0.5 2.1 ± 0.6 2.7 ± 0.5 0.9 ± 0.6 2.82 ± 0.02 
 
 
1.9 ± 0.6 
 
 
8 8.5 ± 0.5 7.2 ± 0.5 4.6 ± 0.5 17.7 ± 0.8 3.9 ± 0.5 4.8 ± 0.5 1.8 ± 0.6 5.79 ± 0.01 
 
 
2.5 ± 0.6 
 
 
24 63.0 ± 3.4 53.8 ± 2.8 39.3 ±1.9 84.4 ± 4.7 36. 3 ± 1.8 31.0 ± 1.5 22.5 ±1.0 57. 6 ± 0.1 
 
 





Note that the Varian spectra AA-5 was calibrated from 1ppm to 15ppm (ref. Fig.3.4), 
therefore all concentrations values found either less or close to 1ppm possessed higher 






































Figure 4.2 Variation of copper conc. of complexes vs. time through Cerasome 
9005 membrane at pH 7.00 
             In Fig. 4.2 above, each complex has the same general trend.  There’s a slow 
induction period of 8h, where after there is a rapid increase in diffusion through the 
Cerasome 9005 membrane. 
The reason for the slow induction period of 8h is probably due to the 
establishment of an equilibrium between the donor phase and the membrane.  
Included in Table 4.2 and Fig.4.2 are the results for CuCl2.2H2O without any 
coordinating ligand.  At pH 7.00, at the concentration used, Cu(OH)2 would precipitate. 
For this reason the pure CuCl2.2H2O was done at pH 4.23.  From Fig.4.2 it is clear that 
the ligands used are able to keep Cu(II) in solution at pH 7.00 and to promote the passage 
of Copper through the membrane.   This effect is shown in Table 4.3 where the 
enhancement factor of the ligand after 24 hrs has been calculated.  This ranges from 6.1 





Table 4.3 Enhancement factor of copper diffusion through Cerasome 9005 












A better way of presenting the results is to calculate the flux and permeability 
coefficient as shown below. 
4.1.2 Flux (J) and permeability coefficient (Kp) calculations 
 The steady state flux and permeability coefficients were calculated from the 
gradient of the curves
1
 in Fig. 4.2.  The values obtained for 8 ligands + CuCl2.2H2O are 





permeability coefficient Kp 10
-6
cm/s.  While the measurements were repeated 3 times, 
effectively only 2 points are used (8hrs, 24hrs) to calculate the slope, hence calculations 
of standard deviation are not really meaningful.  Also, given the variability in membrane 
preparation (≈ 7% error), too much emphasis should not be placed on the low analytical 









s) and permeability coefficient   Kp (10
-
6









CuH(555-N) 3.4  10.7 
CuEDTA 2.9 9.2 
CuAlan 2.0 6.3 
Cu(6UH) 2.2 6.8 
CuGly 4.2 13.1 
CuHomop. 2.0 6.4 
CuPrDH 1.6 5.2 




































DTPAHomop Gly PrDH6UHEDTAH(555-N)   Alan C l
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Figure 4.3 Effect of different ligands on the flux of copper through Cerasome 9005 































Figure 4.4 Influence of ligands on the permeability of copper complexes through 
Cerasome 9005 membrane at pH 7.00 
Fig. 4.4 shows a decrease in permeability coefficient from Gly to Cl
- 
detailed as 
follows: Gly > H(555-N) > EDTA > 6UH > Homop > Alan. > PrDH > DTPA > Cl
-
. 
 The permeability coefficient (Kp) of Cu(II) with amino-acids [Alan (6.310 ± 
0.002)10
-6
cm/s and Gly (13.100± 0.002)10
-6
cm/s] in Fig. 4.4 are comparable to those 
found by Mazurowsky
1
 [Alan (1.90 ± 0.16) 10
-6
cm/s, Gly [(1.62 ± 0.06)10
-6
cm/s].  
Mazurowsky measured diffusion through liposomes and the acceptor phase was buffered 
with potassium phosphate (pH 7.4) which explains the slightly higher values obtained in 
this study.   
 Having established that different ligands were able to enhance the passage of 
Cu(II) through an artificial membrane, the question that has to be asked is why.  In the 
design of new ligands used to promote Cu(II) absorption, it is necessary to identify those 
ligand factors which are important. Previous studies done by Potts and Guy have 
established that for organic compounds, molecular weight and partition coefficient 
(lipophilicity) are important.
7
 A correlation between these factors and the measured flux 
was therefore investigated. 
 






4.2     Partition coefficient 
The Shake-flask method was used in octanol/water mixtures to determine the 
partition coefficient of the Cu(II) complexes.
2
 
The octanol/water partition coefficient (Ko/w) is a quantitative measure of 
lipophilicity of a substance and Table 4.5, along with Figure 4.5, summarize the partition 
coefficients measured in 1-octanol/water mixtures. 
Table 4.5 Logarithm of partition coefficient - Log Ko/w (mean ± SD) of Cu(II) in 
the presence of different ligands in octanol/water mixtures 
 
Order of lipophilicity ligand               - Log Ko/w 
1 Gly 2.66 ± 0.12 
2 H(555-N) 3.00 ± 0.14 
3 6UH 3.02 ± 0.14 
4 EDTA 3.07 ± 0.12 
5 PrDH 3.45 ± 0.12 
6 Homop 3.49 ± 0.14 















1 2 3 4 5 6 7
(-Log Kow)
DTPA6UH HomopGly H(555-N)  EDTA PrDH
 
Figure 4.5 Logarithm of partition coefficient (- Log Ko/w) in 1-octanol/water mixtures 




Table 4.5 and Figure 4.5 show the effect of different ligands on the partition 
coefficients (log Ko/w) of Cu(II) determined at room temperature and pH 7.00.   
The principle of like dissolves like (lipophile-lipophile) along with the lipophilic 
nature of 1-octanol is the main cause of different partition coefficient values observed. 
It was suggested that for a drug to be reasonably lipophilic its log Ko/w value must 
be at least 0.6.
4
 Negative values of log Ko/w indicate that a drug is weakly lipophilic and 
largely hydrophilic.
3   
The negative values of log Ko/w found in this study indicate that 
these complexes are largely hydrophilic and CuGly and CuH(555-N) have higher 
lipophilicity compared to the other 5 complexes.  Similar values have also been found for 
other copper(II) amino acid complexes.
3,4 
The results of Table 4.5 and Fig. 4.5 are very similar to those found in Fig. 4.4 of 
permeability coefficient, where Gly and H(555-N) are higher and very close to each 
other.  
CuPrDH and CuH(555-N) have lower log Ko/w values [(-3.45± 0.12 and -3.00± 
0.14) respectively]  compared to those found by Odisitse and Zvimba at pH 7.4 
[
64
CuPrDH, log Ko/w = -2.35; 
64
CuH(555-N), log Ko/w = -1.39]. This difference can be 
explained by the higher pH used in their study.  At pH 10, the partition coefficients are: 
64
CuPrDH, log Ko/w = -1.72; 
64
CuH(555-N), log Ko/w = -1.14.   
Note that the main purpose of including CuAlan was to compare permeability values 
found in this work with literature values (Mazurowsky
1
).  CuAlan partition coefficients 
were not determined.  
4.3 Data Analysis 
Potts and Guy analysed permeability data using a model which depends only upon 
the size of the drug (MW) and its octanol/water partition coefficient.
7
  Therefore, the aim 
of this analysis was to investigate if there was a correlation between permeability 
coefficient (Kp), octanol/water partition coefficient (Ko/w) and molecular weight (MW) of 
the copper complexes.   So far the different parameters have been assigned to the ligand 
but of course it is the copper complexes of the ligand that are diffusing through the 




For this reason the speciation of the copper, in the presence of the different ligands, 
was calculated.   This is done in the next section. 
4.3.1 Copper speciation in the presence of different ligands 
Table 4.6 gives a list of the speciation of copper in the presence of different ligands 
at pH 7.0. 
Table 4.6 Copper speciation in the presence of different ligands at pH 7.0 
 
 

































The results in Table 4.6 show that in most cases only one copper species is present 
in solution and so it is reasonable to assume that the measured parameters refer to this 
species.    In the case of PrDH, two species predominate. 
4.3.2 Relationship between logarithm of permeability coefficient (Log Kp) and 
molecular weight (MW) of copper complexes 
 Table 4.6 and Fig.4.6 show the investigation of a possible correlation between 
logarithm of permeability coefficient (log Kp) and molecular weight (MW) of the copper 
complexes.  One difficulty with this analysis is knowing which species are present in 
solution.  The copper speciation is dependent on the concentration of ligand used and the 
pH of the solution.  For this reason speciation calculation were done on all the systems, 




 The results are given in Table 4.6.  A second difficulty is knowing the structure of 
the species in solution.   Thermodynamics will tell us the stoichiometry and equilibrium 
constant of the different species but not their structure.    
 For this reason we have to either infer the structure form a knowledge of the ligand 
and the complex stoichiometry or obtain the structure from the original publication where 
these have been done.   This is necessary because the waters of coordination are generally 
not specified in the stochiometry but need to be inferred from the structure.   This has 
been done in Table 4.7.   In some instances it was not possible to unambiguously decide 
on the number of coordinated water molecules as the ligand my be bidentate or tridentate 
and so two alternatives are given.  In calculating, the molecular weight it is assumed that 
the metal is octahedral (tetragonally distorted) with free coordination sites occupied by 
water.   
Table 4.7 Permeability Coefficient (Log Kp), Molecular Weight (MW) and % 
distribution of Cu(II) in copper-ligands species for 7 Copper complexes 
 
Complexes MW (g/mol)           - Log Kp % Cu(II) 
CuGly 
 [Cu(Gly)2(H2O)2] 










































   




























   Cu(6UH)
 
Figure 4.6 Logarithm of permeability coefficient (-Log Kp) plotted against molecular 
weight (MW) of 7 copper complexes 
  
The coefficient of correlation obtained from Fig.4.6 is R
2
 = 0.0426 ± 0.005,which 
is far from 1 demonstrating that there is no correlation between logarithm of partition 
coefficient and molecular weight (MW) of all 7 complexes.  This conclude that logarithm 
of permeability coefficient is independent of molecular weight (MW) of the copper 
complexes 
4.3.3 Relationship between permeability coefficient (Kp) and octanol/water partition 
coefficient (Log Ko/w) 
A correlation was investigated between permeability coefficient (Kp) and 
octanol/water partition coefficient (Log Ko/w).   





































Figure 4.7 Logarithm of permeability coefficient Log Kp plotted against logarithm 
partition coefficient (Log Ko/w) of 7 copper complexes  
The coefficient of correlation obtained from Fig.4.10 is R
2
 = 0.32 ± 0.01, which is 
again far from 1, demonstrating that there is no correlation between permeability 
coefficient and partition coefficient of all complexes.  This to conclude that permeability 
coefficient does not linearly depend on octanol/water partition coefficient for all copper 
complexes. 
4.3.3  Relationship between permeability coefficient (Log Kp), octanol/water 
partition coefficient (Log Ko/w) and molecular weight (MW) of copper complexes 
Various models, based on Fick’s first law of diffusion, have been used to predict 
the relationship between permeability coefficient and partition coefficient of drugs.
4 
As 
said previously (section 4.3), Potts and Guy analysed permeability data using a model 
which depends only upon the size of the drug (MW) and its octanol/water partition 
coefficient
7
.  The following equation was used to predict skin permeability
8
: 
Log Kp = Log (D
0





Kp= the permeability coefficient; D
0
= the diffusivity of hypothetical molecule 
having zero molecular weight; h = the membrane thickness; f = constant which accounts 
for the difference between the partitioning domain presented by octanol and that 
presented by the membrane lipids; Ko/w = the octanol/water partition coefficient; MW = 
molecular weight, β’ = a constant which includes a conversion factor for the substitution 
of molecular weight for molecular volume.  The Cerasome 9005 membrane thickness 
was (h=0.12cm)  
Multiple linear regression analysis of log Kp upon log Ko/w and MW was used to 
obtain values for β’, Log (D
0
/h) and f. 
 
Table 4.8 Relationship between permeability coefficient Log Kp, partition coefficient 
Log Ko/w(mean ± SD)  and molecular weight (MW) of the copper complexes 
 
 
Complex     - Log Kp (cm/s)    - Log Ko/w MW (g/mol) 
 
CuGly 




































    

























CuEDTA 5.19    3.07 ± 0.12 355.79 
 





The average of intercept Log (D
0
/h), slope (β’) and f found after considering 
species solvated either with 2H2O or 3H2O for Cu(6UH), CuH(555-N) and CuPrDH 
were: Log (D
0
/h) = -4.32 ± 0.03, β’ = - 0.00037 ± 0.00001 and f = 0.28 ± 0.01.  Equation 
25 can be written as follows:  




















Residuals plot of Log Kp
 
 Figure 4.8 Residuals plot of permeability coefficient (Log Kp) measured vs. Log Kp 
predicted  
 Fig.4.8 shows a residuals plot of the multiple linear regression analysis.  The 
biggest error is 0.13 or ≈ 2.5% of the measured values of log Kp.  This gives us 
confidence that equation 25 is a good representation of copper diffusion through the 
Cerasome 9005 membrane. 
 The values of Log Kp ≈ -5 of our copper-ligands systems are in agreement with 
values of Log Kp = -5 predicted by Flynn
5
 (1990).   Flynn used a number of algorithms to 
predict skin permeability and proposed that if Log Ko/w < 0.5 and MW > 150, 





The value of f = 0.28 is in agreement with literature which states that f values 
should be greater than zero
6
.  However, using human nail plates, Kobayashi et al
6
 found f 
to be - 0.160.  Potts and Guy (1992) for a data range [18 < MW < 765; -3 < Log Ko/w < 
6]
7
 found f to be 0.71.  Yi-Bo Liou et al used f = 0.71 in their studies of diffusion through 
the skin of nude mice (buffer solution, pH 7.4).
9
   
The reason why our value of f is < 0.71 may be due to the range of Ko/w values 
for our complexes [-3 < Log Ko/w < -2] as opposed to the literature range, and the 
different membrane used. 
The value of f says something about the lipophilic nature of a membrane via Km. 
Km is the membrane/donor vehicle partition coefficient of the drug and is given by: 
Km = [Ko/w]
f
             (26) 
Equation 26 shows that the lipophilic nature (Km) increases with an increase of f 
value.  A comparison of lipophilic nature of membranes was studied through f values and 
equation 26:  Km = human nail plates (f = -0.16) < Cerasome 9005 (f = 0.28) < human 
skin (f = 0.71). 
These results suggest that Cerasome 9005 behaves as a lipophilic partition 
membrane and human nail plates as a hydrophilic gel membrane. 
The values of Log (D
0
/h), β’ and f found by Flynn were respectively – 2.72, 
0.0061 and 0.71 but our values were -4.32 for Log (D
0
/h), 0.00037 for β’ and 0.28 for f.  
The difference can be due to the nature of membrane used.  Flynn used human skin and 
our study used a membrane mimic of human skin. 
Lien and Gao (1995)
10
 analysed a subset of the Flynn data set.  They 
demonstrated that the number of hydrogen bonds that may be formed by a compound 
(Hb), in addition to molecular weight and biphasic response to hydrophobicity, could 
model skin permeability (unit cm/h) very well: 
Log Kp = 0.84 log Ko/w – 0.07 (log Ko/w)
2
 – 0.27Hb – 1.84 log MW + 4.39                  (28) 
n = 22 and r
2
 = 0.96  
Where, n is the number of compounds analysed and r
2 




This model does emphasise the possible importance of hydrogen bonding.  Our 
study investigated the correlation between permeability coefficient, partition coefficient 
and molecular weight only but did not study influence of hydrogen bonding.  A further 
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Sorenson and Jackson et al. have shown that Cu(II) complexes are effective in reducing 
the inflammation associated with RA
1




Several studies have been carried out to design stable Cu(II) complexes and evaluate their 
dermal absorption through the octanol/water mixture partition coefficient.
9,12
  The 
present study has been designed to investigate a new method of studying dermal 
absorption and to compare these results with partition coefficient measurements.  
The Franz diffusion cell was chosen and modified as a method of dermal absorption 
study because it is cheap, reliable, easy, quick to diffuse samples, and there is no need to 
analyse the composition of both phases but only receptor phase. 
The initial concentration of copper(II) used in the donor phase of modifiez Franz cell was 
constantly 317.5 ppm. 
Cerasome 9005, purchased from Germany (Lipoid company), was chosen as an artificial 
membrane because it mimics stratum corneum, gives reproducible results, is easy to 
prepare and maintain.  Using an artificial membrane does not require ethics permission.
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Ligands EDTA, glycine, alanine, DTPA, PrDH, H(555-N), 6UH and homopiperazine 
were selected for permeability study after a screening of sixteen ligands at pH 7.00. 




Fick’s law of diffusion for a steady-state flux (J) and octanol/water mixtures have been 
used to determine the permeability coefficient (Kp) and partition coefficient (Ko/w).
8
   
Potts and Guy data analysis was used to determine the constants which accounts for the 
difference between the partitioning domain presented by octanol and that presented by 
Cerasome 9005 membrane (f).  This relationship includes a conversion factor for the 
substitution of molecular weight for molecular volume (β’) and the diffusivity of 









The diffusion of the copper complexes was studied for 24hrs after establishing a steady 
state flux that was achieved after 8 hrs using alanine and homopiperazine as ligands.  
This steady state validated the modified Franz cells used. 
Phosphate buffered saline (PBS) in donor and acceptor phase of modified Franz cells was 
replaced by water (MQ-water) because PBS would compete with the ligands and 
affecting the steady state of flux.
10
 
The permeability coefficient (Kp) values of complexes with amino-acids were 
comparable to those found by Mazurowsky through nail-plates.
11
 This comparison again 
validated the modified Franz cells used in this study. 
It was observed that the ligand affects dermal absorption of copper complexes.  In fact, 
Gly and H(555-N) with Kp respectively equalled to 13.1 10
-6
cm/s and 10.7 10
-6
cm/s were 
found to enhance the most copper diffusion through Cerasome 9005 membrane. 
The lipophilicity of CuH(555-N) through  its partition coefficient (Log Ko/w) = -3.00 was 
found to be less than CuGly and higher than the rest of complexes.  The negative values 
of log Ko/w found in this study indicate that these complexes are largely hydrophilic. 
In terms of correlation between parameters, no correlation was found between molecular 
weight and logarithm of partition coefficient, permeability coefficient and molecular 
weight, permeability coefficient and formation constant Log β110 and permeability 
coefficient and % distribution of Cu(II) in copper-ligands systems. 
Multiple linear regression analysis of log Kp upon log Ko/w and MW provided values of 
slope β’= - 0.00037 ± 0.00001, intercept Log (D
0
/h) = - 4.32 ± 0.03 and f = 0.28 ± 0.01.   
D
0
 and β’ were considered constant and the value of f = 0.28 was in agreement with 
literature which states that f value should be greater than zero.
6
 A value of f = -0.16 was 
found by Kobayashi et al
13
 using human nail plates and f = 0.71 was found by Potts and 
Guy using human skin.
8
   
Cerasome 9005 membrane used in this research was confirmed to be lipophilic through 




Potts and Guy model did not study the influence of hydrogen bonding.  Therefore, a 
further investigation based on the equation of Lien and Gao
14
 will be useful. 
The octanol/water partition coefficient makes a greater contribution to the permeability 
coefficient than molecular weight.  Permeability coefficient of the copper complexes 
increases when partition coefficient increases, this was observed only for CuGly, 
CuH(555-N), CuPrDH and CuHomop. 
The ligand H(555-N) [N-2[2-(2-aminoethylamino)ethyl]picolinamide] will require  
particular attention for further dermal absorption studies because of permeability 
coefficient and partition coefficient values found in this research. 
CuH(555-N) concentration value after 24 hrs (19.85 ± 0.22)% was found to be very close 




CuH(555-N) in vivo with white mice (albino) 24 hrs 
post-injection in carcass (19.12 ± 3.44) %, 10.65 % less through urine (30.50 ± 2.30) and 
19.31 % higher through blood organ.  This difference can be explained in vitro study 
done with artificial membrane Cerasome 9005 in this research.  
The partition coefficient values with radioactive copper were found by Zvimba and 
Odisitse to be a function of pH.  Therefore, a further investigation on the effect of pH 
upon partition coefficient of copper will be useful. 
Speciation calculations show that the speciation is very dependent on pH.  It would 
therefore be interesting to see the effect of pH upon copper flux.  By varying the pH it 
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